The Pittsburgh spinout is building a precision diagnostic platform that uses genomics to underpin research into conditions such as chronic pancreatic disease.
Ariel Precision Medicine, a US-based genomics spinout from University of Pittsburgh focused on pancreatic diseases, has obtained $1m in funding to date, the Pittsburgh Post-Gazette reported on Monday.
The publication named Innovation Works and Pittsburgh Life Sciences Greenhouse as investors along with undisclosed backers.
Ariel is developing a genomics-based cure for conditions such as chronic pancreatic disease, a persistent inflammation of the pancreas with symptoms such as abdominal pain, nausea and vomiting.
The PancreasDx precision diagnostics platform targets 12 genes…
